{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:34:32Z","timestamp":1771018472519,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ijantimicag.2014.10.008","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T10:59:30Z","timestamp":1415271570000},"page":"221-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review"],"prefix":"10.1016","volume":"45","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriakos K.","family":"Trigkidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos Z.","family":"Vardakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MCC.0b013e328330abcf","article-title":"Aerosolized antibiotics in critically ill ventilated patients","volume":"15","author":"Palmer","year":"2009","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0020","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.prrv.2006.04.183","article-title":"Other medications for aerosol delivery","volume":"7","author":"Rubin","year":"2006","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0025","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00003495-200767060-00006","article-title":"Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia","volume":"67","author":"Wood","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2013.11.005","article-title":"How can we bring high drug doses to the lung?","volume":"86","author":"Claus","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0035","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0954-6111(11)70021-X","article-title":"Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics","volume":"105","author":"Ballmann","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10096-013-1876-y","article-title":"Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review","volume":"32","author":"Gaspar","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0045","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2165\/11318500-000000000-00000","article-title":"Emerging treatments in cystic fibrosis","volume":"69","author":"Jones","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0050","unstructured":"US Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA. \u3008http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0055","series-title":"Human medicines","author":"European Medicines Agency. European Public Assessment Reports","year":"2014"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0060","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1128\/AAC.02421-13","article-title":"Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies","volume":"58","author":"Okusanya","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0065","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0070","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jac\/dkm385","article-title":"Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis","volume":"60","author":"Ioannidou","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0075","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1753465810366858","article-title":"New treatment options for bronchiectasis","volume":"4","author":"Metersky","year":"2010","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2013.10.019","article-title":"Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation","volume":"86","author":"Hoppentocht","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0090","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/jps.23705","article-title":"Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis","volume":"102","author":"Hickey","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0095","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation","volume":"29","author":"Monforte","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00148581-200709050-00003","article-title":"Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy","volume":"9","author":"Shankar","year":"2007","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0110","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s40265-013-0141-0","article-title":"Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"73","author":"McKeage","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0125","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s15010-009-9148-6","article-title":"Inhaled anti-infective agents: emphasis on colistin","volume":"38","author":"Michalopoulos","year":"2010","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0135","article-title":"Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study","author":"Tiddens","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0140","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1517\/14656566.2013.831070","article-title":"Inhaled aztreonam lysine: an evidence-based review","volume":"14","author":"Hutchinson","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/sur.2006.042","article-title":"Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study","volume":"8","author":"Claridge","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0150","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1592\/phco.22.12.972.33596","article-title":"Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients","volume":"22","author":"Wood","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1469-0691.2004.00806.x","article-title":"Use of inhaled ampicillin\u2013sulbactam against multiresistant Acinetobacter baumannii in bronchial secretions of intensive care unit patients","volume":"10","author":"Horianopoulou","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.201011-1894OC","article-title":"Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"184","author":"Lu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0165","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00254674","article-title":"Nosocomial Gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen","volume":"12","author":"Stoutenbeek","year":"1986","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcrc.2007.10.037","article-title":"Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa","volume":"23","author":"Radhakrishnan","year":"2008","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0175","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(81)90588-2","article-title":"Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"2","author":"Hodson","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0180","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0007-0971(87)90161-6","article-title":"Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa","volume":"81","author":"Stead","year":"1987","journal-title":"Br J Dis Chest"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0185","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.arbr.2012.07.012","article-title":"Maintenance treatment with inhaled ampicillin in patients with cystic fibrosis and lung infection due to methicillin-sensitive Staphylococcus aureus","volume":"48","author":"Ma\u00edz","year":"2012","journal-title":"Arch Broncopneumol"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-3476(82)80726-9","article-title":"Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin","volume":"101","author":"Nolan","year":"1982","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0195","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0022-3476(71)80026-4","article-title":"Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation","volume":"78","author":"Huang","year":"1971","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0200","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jcf.2013.04.013","article-title":"Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis","volume":"12","author":"Wang","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0205","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ppul.20983","article-title":"Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient","volume":"44","author":"Ma\u00edz","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jcf.2008.02.005","article-title":"Successful treatment of cepacia syndrome with combination nebulised and intravenous antibiotic therapy","volume":"7","author":"Weidmann","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0215","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0220","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/jcp.40.8.830","article-title":"Simple method of monitoring colonising microbial load in chronic bronchial sepsis: pilot comparison of reduction in colonising microbial load with antibiotics given intermittently and continuously","volume":"40","author":"Currie","year":"1987","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0225","first-page":"214","article-title":"The use of aerosol penicillin and streptomycin in bronchopulmonary infections","volume":"73","author":"Farber","year":"1950","journal-title":"Calif Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0230","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/bmj.1.5697.663","article-title":"Treatment of severe Pseudomonas infections of the bronchi","volume":"1","author":"Pines","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0235","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jam.1994.7.345","article-title":"Nebulizer therapy with antibiotics in chronic suppurative lung disease","volume":"7","author":"el-Din","year":"1994","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(46)91998-8","article-title":"Inhaled penicillin in bronchial infections","volume":"2","author":"Southwell","year":"1946","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0245","first-page":"593","article-title":"Nebulized amoxicillin in chronic purulent bronchiectasis","volume":"7","author":"Stockley","year":"1985","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0250","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/thx.41.7.559","article-title":"Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation","volume":"41","author":"Hill","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0255","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/CCM.0b013e31817c0f9e","article-title":"Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit","volume":"36","author":"Palmer","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0260","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1164\/rccm.201312-2161OC","article-title":"Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit","volume":"189","author":"Palmer","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0265","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s15010-006-5107-7","article-title":"A holistic approach to MRSA eradication in critically ill patients with MRSA pneumonia","volume":"34","author":"Wenisch","year":"2006","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0270","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ppul.10231","article-title":"Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol","volume":"36","author":"Solis","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0275","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00006454-199003000-00017","article-title":"Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus","volume":"9","author":"Weathers","year":"1990","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/106002809202600214","article-title":"Aerosolized vancomycin therapy facilitating nursing home placement","volume":"26","author":"Gradon","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0285","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1440-1843.2009.01647.x","article-title":"Aerosolized vancomycin for the treatment of MRSA after lung transplantation","volume":"15","author":"Hayes","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0290","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1099-0496(199810)26:4<287::AID-PPUL9>3.0.CO;2-#","article-title":"Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"26","author":"Ma\u00edz","year":"1998","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0295","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0300","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0305","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0315","unstructured":"US National Institutes of Health. Clinical trials. \u3008https:\/\/clinicaltrials.gov\/\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0320","unstructured":"Yim J-J. Aerosolized vancomycin in methicillin-resistant Staphylococcus aureus pneumonia under mechanical ventilation. NCT01925066. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01925066?term=NCT01925066&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0325","unstructured":"Boyle MP, Dasenbrook E. Persistent methicillin resistant Staphylococcus aureus eradication protocol (PMEP). NCT01594827. \u3008https:\/\/clinicaltrials.gov\/ct2\/results?term=NCT01594827&Search=Search\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0330","unstructured":"Dasenbrook E. Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients. NCT01746095. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01746095?term=NCT01746095&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0335","unstructured":"Flume P. Trial of Aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. NCT01270347. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01270347?term=NCT01270347&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0340","unstructured":"Flume P. MP-376 (Aeroquin\u2122, levofloxacin for inhalation) in patients with cystic fibrosis. NCT01180634. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01180634?term=NCT01180634&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0345","unstructured":"Froehlich J. Phase 3 study with dual release ciprofloxacin for inhalation in non-CF bronchiectasis (ORBIT-4). NCT02104245. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02104245?term=NCT02104245&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0350","unstructured":"Director BS. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 1). NCT01764841. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764841?term=NCT01764841&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0355","unstructured":"Director BS. Ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 2). NCT02106832. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02106832?term=%2C+NCT02106832&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0360","unstructured":"Froehlich J. Phase 3 study with dual release ciprofloxacin for inhalation in non-CF bronchiectasis (ORBIT-3). NCT01515007. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01515007?term=NCT01515007&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0365","unstructured":"Kollef M. Aerosolized amikacin and fosfomycin in mechanically ventilated patients with Gram-negative pneumonia (IASIS). NCT01969799. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01969799?term=NCT01969799&rank=1\u3009 [accessed 27 October 2014]."},{"key":"10.1016\/j.ijantimicag.2014.10.008_bib0370","unstructured":"Pharma C. Aerosolized amikacin and fosfomycin in mechanically ventilated patients with Gram-negative and\/or Gram-positive bacterial colonization. NCT02218359. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02218359?term=NCT02218359&rank=1\u3009 [accessed 27 October 2014]."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791400329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791400329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T23:22:47Z","timestamp":1565997767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791400329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S092485791400329X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.10.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}